Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling 1,420,000 shares, an increase of 24.6% from the August 31st total of 1,140,000 shares. Currently, 4.1% of the company’s stock are short sold. Based on […]
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 1,040,000 shares, a decline of 67.3% from the July 15th total of 3,180,000 shares. Based on an average trading volume of 4,090,000 shares, the days-to-cover […]
Piper Sandler initiated coverage on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a report released on Friday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $11.00 price objective on the stock. Other research analysts have also recently issued research reports about the stock. Wedbush upgraded shares of Black […]
Piper Sandler initiated coverage on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a report published on Friday, MarketBeat.com reports. The firm issued an overweight rating and a $11.00 target price on the stock. Several other equities analysts also recently issued reports on BDTX. Stifel Nicolaus raised shares of Black Diamond Therapeutics from […]
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Free Report) major shareholder Growth N. V. Biotech bought 1,000,000 shares of the business’s stock in a transaction that occurred on Friday, June 30th. The shares were bought at an average price of $5.00 per share, with a total value of $5,000,000.00. Following the completion of the purchase, the […]